San Francisco Sentry Investment Group’s Perspective Therapeutics CATX Stock Holding History

San Francisco Sentry Investment Group’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-3,750	Closed	-$82K	–	628
2014 Q1	$82K	Hold	3,750	–	–	0.03%	294
2013 Q4	$19K	Hold	3,750	–	–	0.01%	435
2013 Q3	$25K	Hold	3,750	–	–	0.01%	389
2013 Q2	$18K	Buy	+3,750	New	+$20.2K	0.01%	417

Other funds holding CATX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MHP

Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

San Francisco Sentry Investment Group's CATX Position: Q2 2014 in Review

San Francisco Sentry Investment Group sold out of Perspective Therapeutics (CATX) in Q2 2014, closing a stake of 3,750 shares — an estimated $82K sold.

San Francisco Sentry Investment Group first reported a position in CATX in Q2 2013 and held it in 4 quarters. The position peaked at $82K in Q1 2014. 26 funds tracked by Wall St. Rank hold CATX as of Q2 2014.

San Francisco Sentry Investment Group reported no remaining Perspective Therapeutics position as of Q2 2014 after selling out during the quarter.
San Francisco Sentry Investment Group sold 3,750 Perspective Therapeutics shares in Q2 2014, an estimated $82K.
San Francisco Sentry Investment Group first reported a position in Perspective Therapeutics in Q2 2013 and held it in 4 quarters.
San Francisco Sentry Investment Group's Perspective Therapeutics position peaked at $82K in Q1 2014.
26 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2014.

Based on San Francisco Sentry Investment Group's 13F filing for Q2 2014, filed 18 Jul 2014.